與全球學術和非營利組織的合作協議條款及條件：2021-2026

本報告全面分析了製藥和生物技術公司與學術和非營利研究機構之間的合作關係。報告專為業務拓展、許可和研發策略專業人士設計，深入剖析了企業如何與大學、研究機構和非營利組織建立合作關係，以加速創新並開發新療法。

這份經過全面修訂和更新的報告分析了自2021年以來簽署的數千份學術和非營利機構合作協議，全面概述了生命科學公司如何與研究機構在發現、開發和商業化活動中合作。

每份協議記錄均包含可用的財務資訊以及指向詳細線上合約記錄的連結。對於已公開備案的協議，本報告還提供向監管機構提交的原始合約文件的存取權限，方便用戶查閱合作夥伴之間協商的詳細條款。

本報告結合了全面的合約資料、財務基準以及實際合約文件的存取權限，為評估學術合作機會、建立研究夥伴關係以及更有效地進行合約談判提供了寶貴的見解。

主要優勢

• 顯著縮短研究時間

您無需搜尋多個資料庫、新聞稿和監管文件，即可存取包含數千份學術和非營利合作協議的統一資源。

• 學術合作協議結構基準分析

您可以深入了解製藥和生技公司如何與大學和非營利組織建立合作關係，包括研究合作、授權協議和開發夥伴關係。

• 財務條款的可靠分析

仔細審查可用的財務數據，包括關鍵合約金額、預付款、里程碑付款和特許權使用費結構，以對類似合作的財務價值進行基準分析。

• 查閱實際合約文件

在條件允許的情況下，您可以查閱提交給監管機構的實際學術合作協議，並深入了解通常不會公開的合約條款。

• 識別最活躍的學術合作方

您可以了解哪些製藥公司、研究機構和非營利組織在合作方面最為活躍。

• 追蹤產業合作趨勢

依技術領域、治療領域和研發階段分析自 2019 年以來的學術合作活動。

目錄

摘要整理

第一章：引言

第2章 跟學術機構·非營利團體的契約動向

• 年度合作趨勢
• 最活躍的合作夥伴
• 與學術機構和非營利組織的合作：依合約類型劃分
• 與學術機構和非營利組織的合作：依治療領域劃分
• 與學術機構和非營利組織的合作：依技術類型劃分
• 合約條款分析
  • 合約總金額
  • 預付款
  • 里程碑付款
  • 特許權使用費率

第三章：與主要學術機構和非營利組織的合約

• 與主要學術機構和非營利組織的合約：依金額劃分

第四章：最活躍的學術和非營利合作夥伴

• 最活躍的學術和非營利合作夥伴
• 簡介最活躍的學術和非營利合作夥伴公司

第五章：與學術機構和非營利組織的合約目錄

• 與學術機構和非營利組織的合約目錄

第六章：與學術機構和非營利組織的合約：依技術類型劃分

附錄

• 附錄 1 - 學術與非營利合作夥伴關係：依公司（A-Z）劃分
• 附錄 2 - 學術與非營利合作夥伴關係：依發展階段劃分
• 附錄 3 - 學術與非營利合作夥伴關係：依合約類型劃分
• 附錄 4 - 學術與非營利合作夥伴關係：依治療領域劃分
• 附錄 5 - 合約類型定義
• 附錄 6 - 更多信息
• 關於 Biopharma Research Ltd
• 當前合作夥伴關係
• 當前合約
• 近期合作夥伴關係報告標題

Benchmark Academic Collaboration Strategies Across the Global Life Sciences Industry

The Global Academic and Non-Profit Partnering Terms and Agreements 2021-2026 report provides a comprehensive analysis of partnerships between pharmaceutical and biotechnology companies and academic or non-profit research institutions. Designed for business development, licensing, and research strategy professionals, the report delivers detailed insight into how companies structure collaborations with universities, research institutes, and non-profit organizations to accelerate innovation and advance new therapies.

Fully revised and updated, the report analyzes thousands of academic and non-profit partnership agreements announced since 2021, providing an extensive view of how life sciences companies collaborate with research institutions across discovery, development, and commercialization activities.

Each deal record includes financial information where available and links to detailed online deal records. Where agreements have been publicly filed, the report also provides access to the underlying contract documents submitted to regulators, allowing users to review the detailed terms negotiated between partners.

By combining comprehensive deal data, financial benchmarking, and access to real contract documents, the report provides valuable intelligence for evaluating academic collaboration opportunities, structuring research partnerships, and negotiating more effective agreements.

Key Benefits

• Save Significant Research Time

Access a consolidated resource covering thousands of academic and non-profit partnering agreements instead of searching multiple databases, press releases, and regulatory filings.

• Benchmark Academic Collaboration Deal Structures

Understand how pharmaceutical and biotechnology companies structure partnerships with universities and non-profit institutions, including research collaborations, licensing arrangements, and development partnerships.

• Analyze Financial Terms with Confidence

Review available financial data-including headline deal values, upfront payments, milestone payments, and royalty structures-to benchmark the financial value of comparable partnerships.

• Access Real Contract Documents

Where available, explore actual academic collaboration agreements filed with regulators, providing insight into contractual provisions that are rarely disclosed publicly.

• Identify the Most Active Academic Dealmakers

Discover which pharmaceutical companies, research institutions, and non-profit organizations are most active in forming academic partnerships.

• Track Industry Collaboration Trends

Analyze academic partnering activity since 2019 across technologies, therapeutic areas, and development stages.

What's Included in the Report

Analysis of academic and non-profit partnering trends since 2021

Overview of academic collaboration structures and financial models

Review of leading academic partnerships by deal value

Profiles of the most active academic and non-profit dealmakers

Detailed analysis of deals organized by company, development stage, technology type, and therapy area

A comprehensive directory of academic partnering agreements

Links to online deal records and contract documents where available

Deals are indexed across multiple categories-including company A-Z, deal value, development stage, technology type, and therapy target-allowing users to quickly identify comparable transactions.

Due Diligence Insights from Real Agreements

By reviewing actual academic collaboration contracts, the report enables users to evaluate key partnership provisions such as:

• Rights granted or licensed under the collaboration
• Financial payment structures and milestone triggers
• Intellectual property ownership and licensing scope
• Research, development, and commercialization responsibilities
• Exclusivity provisions and territorial rights
• Contract duration, termination clauses, and governance structures
• Access to real agreements provides insight into the detailed terms negotiated between companies and research institutions-information rarely disclosed in press releases or standard deal databases.
• Why This Report Matters
• Partnerships with universities and non-profit research institutions play a critical role in early-stage innovation across the life sciences industry. These collaborations enable companies to access breakthrough research, share development risk, and accelerate the translation of scientific discoveries into commercial therapies.
• By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate academic partnership opportunities, structure stronger research collaborations, and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Academic and Non-Profit dealmaking

• 2.1. Introduction
• 2.2. Academic and Non-Profit partnering over the years
• 2.3. Most active Academic and Non-Profit dealmakers
• 2.4. Academic and Non-Profit partnering by deal type
• 2.5. Academic and Non-Profit partnering by therapy area
• 2.6. Academic and Non-Profit partnering by technology type
• 2.7. Deal terms for Academic and Non-Profit partnering
  • 2.7.1 Academic and Non-Profit partnering headline values
  • 2.7.2 Academic and Non-Profit deal upfront payments
  • 2.7.3 Academic and Non-Profit deal milestone payments
  • 2.7.4 Academic and Non-Profit royalty rates

Chapter 3 - Leading Academic and Non-Profit deals

• 3.1. Introduction
• 3.2. Top Academic and Non-Profit deals by value

Chapter 4 - Most active Academic and Non-Profit dealmakers

• 4.1. Introduction
• 4.2. Most active Academic and Non-Profit dealmakers
• 4.3. Most active Academic and Non-Profit partnering company profiles

Chapter 5 - Academic and Non-Profit contracts dealmaking directory

• 5.1. Introduction
• 5.2. Academic and Non-Profit contracts dealmaking directory

Chapter 6 - Academic and Non-Profit dealmaking by technology type

Appendices

• Appendix 1 - Academic and Non-Profit deals by company A-Z
• Appendix 2 - Academic and Non-Profit deals by stage of development
• Appendix 3 - Academic and Non-Profit deals by deal type
• Appendix 4 - Academic and Non-Profit deals by therapy area
• Appendix 5 - Deal type definitions
• Appendix 6 - Further reading
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Academic and Non-Profit partnering since 2021
• Figure 2: Active Academic and Non-Profit dealmaking activity since 2021
• Figure 3: Academic and Non-Profit partnering by deal type since 2021
• Figure 4: Academic and Non-Profit partnering by disease type since 2021
• Figure 5: Academic and Non-Profit partnering by technology type since 2021
• Figure 6: Academic and Non-Profit deals with a headline value
• Figure 7: Academic and Non-Profit deals with an upfront value
• Figure 8: Academic and Non-Profit deals with a milestone value
• Figure 9: Academic and Non-Profit deals with a royalty rate value
• Figure 10: Top Academic and Non-Profit deals by value since 2021
• Figure 11: Most active Academic and Non-Profit dealmakers since 2021